NASDAQ:ERAS Erasca (ERAS) Stock Forecast, Price & News $2.71 +0.09 (+3.44%) (As of 05/31/2023 ET) Add Compare Share Share Today's Range$2.59▼$2.7450-Day Range$2.57▼$3.1552-Week Range$2.49▼$10.74Volume740,612 shsAverage Volume937,893 shsMarket Capitalization$408.10 millionP/E RatioN/ADividend YieldN/APrice Target$11.33 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Erasca MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside318.2% Upside$11.33 Price TargetShort InterestBearish12.52% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.58Based on 5 Articles This WeekInsider TradingAcquiring Shares$339,200 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($1.29) to ($1.54) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.17 out of 5 starsMedical Sector325th out of 1,006 stocksPharmaceutical Preparations Industry149th out of 492 stocks 3.5 Analyst's Opinion Consensus RatingErasca has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.33, Erasca has a forecasted upside of 318.2% from its current price of $2.71.Amount of Analyst CoverageErasca has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted12.52% of the float of Erasca has been sold short.Short Interest Ratio / Days to CoverErasca has a short interest ratio ("days to cover") of 11.2, which indicates bearish sentiment.Change versus previous monthShort interest in Erasca has recently decreased by 9.22%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldErasca does not currently pay a dividend.Dividend GrowthErasca does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ERAS. Previous Next 2.0 News and Social Media Coverage News SentimentErasca has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Erasca this week, compared to 1 article on an average week.Search InterestOnly 4 people have searched for ERAS on MarketBeat in the last 30 days. This is a decrease of -91% compared to the previous 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Erasca insiders have bought more of their company's stock than they have sold. Specifically, they have bought $339,200.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders37.50% of the stock of Erasca is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions65.75% of the stock of Erasca is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Erasca are expected to decrease in the coming year, from ($1.29) to ($1.54) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Erasca is -1.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Erasca is -1.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioErasca has a P/B Ratio of 1.05. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Erasca (NASDAQ:ERAS) StockErasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.Read More Receive ERAS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Erasca and its competitors with MarketBeat's FREE daily newsletter. Email Address ERAS Stock News HeadlinesMay 31, 2023 | finance.yahoo.comErasca to Host Virtual Investor Event on Pipeline Updates with a Focus on ERAS-007 ERK InhibitorMay 25, 2023 | finance.yahoo.comErasca to Present Promising Preliminary HERKULES-3 Phase 1b Data at the 2023 ASCO Annual MeetingJune 1, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...May 25, 2023 | msn.comErasca Earnings PreviewMay 25, 2023 | finance.yahoo.comWith 42% stake, Erasca, Inc. (NASDAQ:ERAS) seems to have captured institutional investors' interestMay 16, 2023 | 247wallst.comGoldman Sachs Maintains Erasca Buy RecommendationMay 16, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Boston Scientific (BSX) and Erasca (ERAS)May 16, 2023 | msn.comGoldman Sachs Maintains Erasca (ERAS) Buy RecommendationJune 1, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...May 16, 2023 | markets.businessinsider.comErasca (ERAS) Receives a Buy from Goldman SachsMay 16, 2023 | finance.yahoo.comErasca Further Strengthens Business Leadership with Two Key PromotionsMay 15, 2023 | markets.businessinsider.comMizuho Securities Sticks to Their Buy Rating for Erasca (ERAS)May 15, 2023 | finance.yahoo.comErasca Reports First Quarter 2023 Financial Results and Business UpdatesMay 2, 2023 | finance.yahoo.comErasca to Present at the Bank of America Securities 2023 Health Care ConferenceMay 1, 2023 | finance.yahoo.comErasca Granted FDA Fast Track Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 in Patients with GlioblastomaApril 26, 2023 | finance.yahoo.comErasca Announces Two Poster Presentations at the 2023 ASCO Annual MeetingApril 25, 2023 | finance.yahoo.comErasca Announces Publication of Promising Clinical Data Supporting the Therapeutic Potential of Naporafenib in Combination with Trametinib in NRAS-Mutant MelanomaApril 22, 2023 | americanbankingnews.comErasca, Inc. (NASDAQ:ERAS) Short Interest Up 12.0% in MarchApril 18, 2023 | markets.businessinsider.comErasca (ERAS) Gets a Buy from Mizuho SecuritiesApril 18, 2023 | ca.finance.yahoo.comErasca, Inc. (ERAS) Stock Price, News, Quote & History - Yahoo FinanceApril 18, 2023 | finance.yahoo.comErasca Presents Promising Initial Phase 1b Dose Escalation Data from FLAGSHP-1 for ERAS-601 Plus Cetuximab in Patients with Advanced Solid Tumors at the 2023 AACR Annual MeetingApril 13, 2023 | americanbankingnews.comAlexander W. Casdin Buys 20,000 Shares of Erasca, Inc. (NASDAQ:ERAS) StockApril 10, 2023 | markets.businessinsider.comMizuho Securities Remains a Buy on Erasca (ERAS)April 10, 2023 | finance.yahoo.comErasca Strengthens Clinical and Regulatory Leadership with Two Key Appointments as Company Transitions to Late-Stage DevelopmentApril 1, 2023 | americanbankingnews.comErasca (NASDAQ:ERAS) Earns Buy Rating from Analysts at MizuhoMarch 31, 2023 | seekingalpha.comErasca spikes as CEO reports stock purchaseMarch 31, 2023 | msn.comMizuho Initiates Coverage of Erasca (ERAS) with Buy RecommendationSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ERAS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Erasca and its competitors with MarketBeat's FREE daily newsletter. Email Address ERAS Company Calendar Last Earnings3/23/2023Today5/31/2023Next Earnings (Estimated)8/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ERAS CUSIPN/A CIK1761918 Webwww.erasca.com Phone858-465-6511FaxN/AEmployees123Year FoundedN/APrice Target and Rating Average Stock Price Forecast$11.33 High Stock Price Forecast$15.00 Low Stock Price Forecast$9.00 Forecasted Upside/Downside+324.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.87) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-242,800,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-35.81% Return on Assets-29.79% Debt Debt-to-Equity RatioN/A Current Ratio15.59 Quick Ratio15.59 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.57 per share Price / Book1.04Miscellaneous Outstanding Shares150,590,000Free Float94,118,000Market Cap$402.08 million OptionableNot Optionable Beta1.10 Key ExecutivesDr. Jonathan E. Lim M.D. (Age 51)Co-Founder, Chairman & CEO Comp: $850.23kMr. Ebun S. Garner J.D. (Age 51)Esq., Gen. Counsel & Corp. Sec. Comp: $510.98kDr. Wei Lin M.D. (Age 53)Chief Medical Officer Comp: $1MDr. Michael D. Varney Ph.D. (Age 65)Chairman of R&D, Scientific Advisory Board Member and Director Comp: $78.38kDr. David M. Chacko M.D. (Age 39)Chief Financial Officer Dr. Nik Chetwyn Ph.D.Sr. VP of OperationsDr. Lisa Tesvich-Bonora Ph.D.Chief People OfficerMr. Brian L. Baker CPA (Age 56)M.S., MS, CPA, Sr. VP of Fin. Ms. Chandra D. Lovejoy (Age 52)Sr. VP of Regulatory Affairs Dr. Robert Shoemaker Ph.D. (Age 42)Sr. VP of Research More ExecutivesKey CompetitorsAerovate TherapeuticsNASDAQ:AVTESIGA TechnologiesNASDAQ:SIGAArbutus BiopharmaNASDAQ:ABUSAllakosNASDAQ:ALLKPepGenNASDAQ:PEPGView All CompetitorsInsiders & InstitutionsAmeriprise Financial Inc.Bought 10,175 shares on 5/22/2023Ownership: 0.007%International Biotechnology Trust PLCBought 1,426,000 shares on 5/18/2023Ownership: 0.947%JPMorgan Chase & Co.Sold 87,156 shares on 5/18/2023Ownership: 0.037%New York State Common Retirement FundSold 25,000 shares on 5/18/2023Ownership: 0.012%Graham Capital Management L.P.Bought 10,527 shares on 5/16/2023Ownership: 0.007%View All Insider TransactionsView All Institutional Transactions ERAS Stock - Frequently Asked Questions Should I buy or sell Erasca stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Erasca in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ERAS shares. View ERAS analyst ratings or view top-rated stocks. What is Erasca's stock price forecast for 2023? 3 analysts have issued 1-year target prices for Erasca's shares. Their ERAS share price forecasts range from $9.00 to $15.00. On average, they expect the company's share price to reach $11.33 in the next twelve months. This suggests a possible upside of 324.5% from the stock's current price. View analysts price targets for ERAS or view top-rated stocks among Wall Street analysts. How have ERAS shares performed in 2023? Erasca's stock was trading at $4.31 on January 1st, 2023. Since then, ERAS shares have decreased by 38.1% and is now trading at $2.67. View the best growth stocks for 2023 here. Are investors shorting Erasca? Erasca saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 10,340,000 shares, a decrease of 9.2% from the April 30th total of 11,390,000 shares. Based on an average daily volume of 924,800 shares, the days-to-cover ratio is presently 11.2 days. Approximately 12.5% of the company's stock are sold short. View Erasca's Short Interest. When is Erasca's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023. View our ERAS earnings forecast. How were Erasca's earnings last quarter? Erasca, Inc. (NASDAQ:ERAS) announced its quarterly earnings data on Thursday, March, 23rd. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.30) by $0.02. What ETFs hold Erasca's stock? ETFs with the largest weight of Erasca (NASDAQ:ERAS) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC), Principal Healthcare Innovators ETF (BTEC), Invesco Nasdaq Biotechnology ETF (IBBQ), ProShares Ultra Nasdaq Biotechnology (BIB), Fidelity Growth Opportunities ETF (FGRO), When did Erasca IPO? (ERAS) raised $262 million in an initial public offering on Thursday, July 15th 2021. The company issued 17,500,000 shares at $14.00-$16.00 per share. What is Erasca's stock symbol? Erasca trades on the NASDAQ under the ticker symbol "ERAS." Who are Erasca's major shareholders? Erasca's stock is owned by a variety of retail and institutional investors. Top institutional investors include Armistice Capital LLC (4.88%), BlackRock Inc. (3.57%), Bank of America Corp DE (1.98%), Geode Capital Management LLC (1.01%), Renaissance Technologies LLC (0.97%) and International Biotechnology Trust PLC (0.95%). Insiders that own company stock include Alexander W Casdin, Bihua Chen, Jonathan E Lim and Valerie Denise Harding Start. View institutional ownership trends. How do I buy shares of Erasca? Shares of ERAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Erasca's stock price today? One share of ERAS stock can currently be purchased for approximately $2.67. How much money does Erasca make? Erasca (NASDAQ:ERAS) has a market capitalization of $402.08 million. The company earns $-242,800,000.00 in net income (profit) each year or ($1.87) on an earnings per share basis. How many employees does Erasca have? The company employs 123 workers across the globe. How can I contact Erasca? The official website for the company is www.erasca.com. The company can be reached via phone at 858-465-6511 or via email at ir@erasca.com. This page (NASDAQ:ERAS) was last updated on 6/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Erasca, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.